BDTX

1.3353.96%
EB

Elizabeth Buck

Co-Founder & Chief Scientific Officer

Dr. Elizabeth Buck, Ph.D, serves as Chief Scientific Officer and Chief Operating Officer at ASET Therapeutics, LLC. She is Co-Founder of Black Diamond Therapeutics, Inc. She was the Executive Vice President, Discovery and Translational Services at Black Diamond Therapeutics, Inc. (formerly known as Aset Therapeutics, Inc.) since March 2017 until August 2021 and serves as its Chief Scientific Officer since August 11, 2021. She served as Chief Scientific Officer of Therapeutics at MetaStat, Inc. since September 3, 2013. Dr. Buck has expertise in preclinical pharmacology, translational research, and biomarker discovery in oncology. Prior to joining MetaStat, Inc., she served as Assistant Director of Advanced Preclinical Pharmacology at OSI Pharmaceuticals, a wholly owned subsidiary of Astellas Pharma US Inc., where she served since 2005. In this role Dr. Buck was responsible for the advancement of preclinical lead molecules in oncology to IND nomination. She drove the translational research and biomarker strategy for multiple programs including linsitinib, its in Phase 2 development, and is author of more than 30 peer-reviewed publications and patents. Among Dr. Buck's research accomplishments is an improved understanding for how compensatory signaling between receptor tyrosine kinases can lead to resistance to cancer therapeutics including the EGFR inhibitor erlotinib. Dr. Buck received a B.S. in physics from the University of New Hampshire, a Ph.D. in pharmacology from New York University / Mount Sinai School of Medicine, and a fellowship at Sunesis Pharmaceuticals.

Positions